Jardiance 10mg price reduced from ₩618 to ₩582

With its scope of use extended to cover chronic kidney disease

Insurance price ceiling price cut 5.8% from August

Will be applied unilaterally with PVA adjustment to reduce on-site confusion

The maximum insurance price ceiling for the 10 mg flagship dosage form of the SGLT-2 inhibitor diabetes treatment Jardiance Tab (empagliflozin, Boehringer Ingelheim), will be adjusted as reimbursement will also apply to chronic kidney disease.  Jardiance recorded KRW 66.3 billion in outpatient prescriptions (based on UBIST) last year.

 

According to industry sources on the 18th, the insurance price ceiling for Jardiance 10mg will be reduced from KRW 618 to KRW 582 as of August.

 

This is a 5.8% reduction.

 

Along with the price cut, Jardiance 10 mg will also be reimbursed for non-diabetic chronic kidney disease from August.

 

A patient needs to meet all of the following conditions to receive reimbursement for Jardiance 10mg: ▲is on a stable dose of an ACE inhibitor or angiotensin II receptor blocker at the maximum tolerated dose for at least 4 weeks ▲has an eGFR between 20 and 75 ml/min/1.73 m², and ▲urine dipstick test is positive (1+ or higher) or uACR is 200 mg/g or higher.

 

Jardiance is also administered in combination with other standard treatments for kidney disease.

 

Another SGLT-2 inhibitor, dapagliflozin, has also been granted reimbursement for the treatment of chronic kidney disease starting this month.

 

As a result, dapagliflozin-containing drugs and Jardiance, for which no generic versions have been released yet, are now reimbursed not only for diabetes but also for chronic heart failure and chronic kidney disease, greatly expanding their scope of use.

 

In Jardiance’s case, Jardiance Tab 10 tablets will undergo a preemptive price reduction due to its expanded scope of use, resulting in an adjustment of its insurance ceiling price.

 

Originally, the price of Jardiance 10 mg Tab was scheduled to be reduced from KRW 618 to KRW 591 starting in July under the price-volume agreement (Type B, PVA) scheme.

 

 However, considering the potential confusion and administrative burden caused by consecutive price reductions, the government decided to adjust the prices unilaterally starting in August.

 

On the other hand, the price of Jardiance 25mg was reduced from KRW 798 to KRW 762 in July under the PVA.

 

Type B of the PVA scheme refers to cases where the insurance price ceiling has been adjusted under Type A, or where the maximum price has not been negotiated under Type A, and the claims amount for the same product group has increased by more than 60% compared to the previous year's claims amount, or has increased by more than 10% with an increase of KRW 50 billion or more, from the date of initial listing or the date the insurance price ceiling was adjusted through negotiation.

 

The insurance price ceiling is adjusted through the company’s price negotiations with the National Health Insurance Service.

 

As Jardiance is a blockbuster drug with annual prescriptions exceeding KRW 60 billion, healthcare institutions are advised to exercise caution with regard to the price reduction.

 

Jardiance is co-marketed in Korea by Boehringer Ingelheim and Yuhan Corp.